Notice of NHLBI Participation in PA-18-702 "Administrative Supplements for Participation in the Concept to Clinic: Commercializing Innovation (C3i) Program (Admin Supp - Clinical Trial Not Allowed)"

Notice Number: NOT-HL-18-608

Key Dates
Release Date: March 28, 2018

Related Announcements
PA-18-702

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in PA-18-702 "Administrative Supplements for Participation in the Concept to Clinic: Commercializing Innovation (C3i) Program (Admin Supp - Clinical Trial Not Allowed)."   

The following sections of PA-18-702 have been updated to reflect participation of NHLBI participation in this Funding Opportunity Announcement.

Part 1. Overview Information

Components of Participating Organizations
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Heart, Lung, and Blood Institute (NHLBI)

Catalog of Federal Domestic Assistance (CFDA) Number(s) ?93.286, 93.847, 93.865, 93.242, 93.853, 93.837, 93.838, 93.839, 93.233, 93.840  

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)
Mike Pieck
National Heart Lung and Blood Institute (NHLBI)
Telephone: 301-496-2149
Email: NHLBI_SBIR@mail.nih.gov

Grants Management Contact(s)
Ann Marie Brasile Mejac 
National Heart, Lung, and Blood Institute (NHLBI) 
Telephone: 301-435-0164
Email: brasilea@nhlbi.nih.gov

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Mike Pieck
National Heart Lung and Blood Institute (NHLBI)
Telephone: 301-496-2149
Email: NHLBI_SBIR@mail.nih.gov